Sanaz Afiat, MD
Ophthalmology · Edina, MNNPI 1962440610
Payments from drug & device makers
Across 17 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$53
- Glaukos Corporation$43
- Dompe US, Inc.$38
- Tarsus Pharmaceuticals, Inc.$29
- Harrow Eye, LLC$20
- Alcon$18
- plus $89 from 6 others
What the payments were for
- Food & beverage$27394%
- Gifts$176%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 3 | $53 |
| Glaukos Corporation | 2 | $43 |
| Dompe US, Inc. | 2 | $38 |
| Tarsus Pharmaceuticals, Inc. | 2 | $29 |
| Harrow Eye, LLC | 1 | $20 |
| Alcon | 1 | $18 |
| Oyster Point Pharma, Inc. | 1 | $18 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Coopervision Inc. | 1 | $15 |
| Rxsight Inc | 1 | $14 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $14 |
| Sun Pharmaceutical Industries Inc. | 1 | $11 |
How this compares
$290 in reported general payments places this provider in the 45th percentile of 330 ophthalmology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 65 | $93,841 |
| Cyclosporine | 16 | $13,802 |
| Fluorometholone | 133 | $11,922 |
| Latanoprost | 542 | $10,955 |
| RhopressaNetarsudil Mesylate | 12 | $8,329 |
| Timolol Maleate | 490 | $5,726 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $5,725 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 199 | $4,907 |
| Prednisolone Acetate | 87 | $4,457 |
| Brimonidine Tartrate | 101 | $2,680 |
| ValacyclovirValacyclovir Hcl | 47 | $2,292 |
| Doxycycline Hyclate | 32 | $1,822 |
| Doxycycline Monohydrate | 66 | $1,623 |
| Dexamethasone Sodium Phosphate | 23 | $1,224 |
| MoxifloxacinMoxifloxacin Hcl | 28 | $419 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Edina
- Adam MossEdina$65K
- Peter BelinEdina$9K
- Jeffrey StephensEdina$7K
- Tsun Kang ChiangEdina$5K
- Ryan JohnsonEdina$4K
- Jeffrey SandersonEdina$4K
- Rhondi MeiusiEdina$3K
- Christopher StefonowiczEdina$3K
- Edwin RyanMinneapolis$9.6M
- Richard LindstromBloomington$9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.